HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path

Executive Summary

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

You may also be interested in...



Still No Appetite At US FDA For CBD In Food

Three years after similar warnings to make same impression, FDA warns five firms about using in food or beverage products CBD, the cannabinoid most commonly found in US, and delta-8 THC, a subject of ongoing discussion over whether it qualifies as hemp. One firm also warned about CBD in sunscreen.

Studies Find Oil, Topical And Transdermal Hemp Products’ Content Inconsistent With Labeling

JAMA study found 24% of 89 topicals or transdermals labeled correctly for amounts of cannabinoid in the products; JCR study found 54% of 80 CBD oils were accurately labeled, 15% had higher levels and 31% had lower.

Hemp Ingredient Filter Recommended Before Lawful Use Allowed In Supplements In US

Filling in the blanks for which ingredients qualify for definition of hemp could be as difficult and complicated as the question of lawful use, says food and drug attorneys. A DEA rule from legislation de-scheduling hemp left room for confusion on which substances qualify. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel